Inceptua Group – pharma company and service partner – today announces that Philip Gregory has joined Inceptua as Vice President, Head of Asia-Pacific, Clinical Trial Services. Inceptua has offices in both Japan and China where the regional Clinical Trial Services Team provides strategic sourcing and supply of clinical trial materials with associated clinical packaging and labelling solutions, supporting trial sponsors and helping them realize their business goals in Asia

Morphic Therapeutic, a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, announced an oral presentation today highlighting Morphic’s product candidate MORF-057 at the 15th Congress of the European Crohn’s and Colitis Organisation (ECCO). MORF-057 is in development as an oral inhibitor of the α4β7 integrin, a clinically proven target for the treatment of inflammatory bowel diseases (IBD).

Tetra Bio Pharma Inc., a leader in cannabinoid-derived drug discovery and development, today announced it has signed a definitive manufacturing agreement with Vitiprints LLC, for the commercial scale production of CAUMZ™ and HCC011.  This agreement will further protect CAUMZ™ and HCC011 with four additional patents on manufacturing know-how. VITIPRINTS has developed a proprietary and patented manufacturing system, which can be used by Tetra to manufacture its CAUMZ&

Synspira Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to improving the lives of people with cystic fibrosis (CF) and other rare diseases, announced today the company has signed an agreement with the Cystic Fibrosis Foundation to support the development of SNSP003, Synspira's orally delivered non-porcine enzyme replacement therapy (ERT) designed to treat Malabsorption Syndromes. Malabsorption Syndromes are a group of life-threatening disorders that result from de

CNS Pharmaceuticals, Inc., a biotechnology company specializing in the development of novel treatments for brain tumors, today announced its plan to initiate a Phase I clinical trial for Berubicin in pediatric brain cancer in Poland in collaboration with WPD Pharmaceuticals, Inc., a Polish corporation founded by Dr. Waldemar Priebe, the founder of the Company. The Company, in collaboration with WPD, will conduct the upcoming Phase I clinical trial at Children's Memorial Health I

Endonovo Therapeutics, Inc. announced their SofPulse® device is being evaluated at major universities for orthopedic surgeries. SofPulse® is Endonovo’s FDA-Cleared, non-invasive device utilized for the reduction of postoperative pain and edema. SofPulse® represents a low-cost drug-free solution for reducing opioid usage, accelerating patient recovery and preventing opioid addiction following surgical procedures. This non-invasive and non-pharmacologic therapy has n

Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer,  announced that it has entered into an amendment of its collaboration, license and option agreement with Aurigene Discovery Technologies, Ltd. (Aurigene). Under the terms of the amended agreement, Aurigene will fund and conduct a Phase 2b/3 randomized study evaluating CA-170, an orally available, dual inhibitor of VISTA and PDL1, in combination with chemoradiation, in a

CPhI’s ASEAN Pharma 2020 Report points to Thailand and Indonesia having the largest near-term generics export potential, as regional executives come out in favour of an ASEAN-wide track and trace scheme. The report’s findings which have been released ahead of CPhI Southeast Asia (4-6 March, Bangkok) summarize the opportunit

BioMotiv, a mission-driven drug development accelerator associated with The Harrington Project for discovery and development, that advances breakthrough discoveries from research institutions into therapeutics, and Bristol-Myers Squibb Company  announced the launch of Anteros Pharmaceuticals, a biotechnology company focused on developing a new class of drugs for fibrotic and other inflammatory diseases. The intellectual property behind Anteros was first developed by Yale University and i

Eminence Business Media’s “3rd Annual Pharma Project & Portfolio Management Summit 2020” concluded on January 23rd & 24th, 2020 at Hotel Hilton, Mumbai. The theme of the summit was “Grooming Project & Portfolio Management teams for opportunities & uncertainties”. The event was an outstanding success with 100+ delegates attending the summit with I2E Consulting, Innoventic Research & Business & Product Dossier Solutions India Pvt. Ltd. partn